A phase 2 study of LIVNate for the treatment of NASH
Latest Information Update: 20 May 2020
At a glance
- Drugs Pegipanermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
Most Recent Events
- 14 May 2020 According to an INmune Bio media release, due to COVID-19 pandemic the company now expects to enroll first patient in mid-2021.
- 13 Mar 2020 New trial record
- 11 Mar 2020 According to an INmune Bio media release, the company expects to enroll first patient in this study in mid-2020.